The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer

Christopher Darr, Ulrich Krafft, Boris Hadaschik, Stephan Tschirdewahn, Sabina Sevcenco, Anita Csizmarik, P. Nyírády, Zsófia Küronya, Henning Reis, Agnieszka Maj-Hes, Shahrokh F. Shariat, Gero Kramer, Tibor Szarvas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy. Responsive patients were retreated by repeated series of DOC. Results were compared with the clinical parameters as well as overall (OS) and disease-specific survival (DSS). Results: YKL-40 but not PSA serum levels were significantly higher in patients with baseline resistance to DOC (p = 0.035). Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008). High YKL-40 levels were associated with shorter OS (p = 0.037) and DSS (p = 0.017) in patients who received DOC in the first-line setting. In multivariable analysis, ECOG performance status (p = 0.009), presence of any metastases (p = 0.016) and high PSA levels (p = 0.005) remained independent predictors for DSS. Conclusions: YKL-40 may help to identify patients with baseline resistance to DOC and therefore may help to optimize treatment decisions. In accordance, high pre-treatment YKL-40 serum levels were associated with shorter OS and DSS in patients who received DOC as first-line therapy.

Original languageEnglish
Pages (from-to)65-73
Number of pages9
JournalUrologia Internationalis
Volume101
Issue number1
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

docetaxel
Prostatic Neoplasms
Drug Therapy
Prostate-Specific Antigen
Survival
Serum
Neoplasm Metastasis
Therapeutics
Castration
Prostatectomy
Drug Resistance

Keywords

  • Castratation-resistant prostate cancer
  • Docetaxel
  • Drug resistance
  • Prognosis
  • Prostate cancer
  • YKL-40

ASJC Scopus subject areas

  • Urology

Cite this

Darr, C., Krafft, U., Hadaschik, B., Tschirdewahn, S., Sevcenco, S., Csizmarik, A., ... Szarvas, T. (2018). The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. Urologia Internationalis, 101(1), 65-73. https://doi.org/10.1159/000489891

The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. / Darr, Christopher; Krafft, Ulrich; Hadaschik, Boris; Tschirdewahn, Stephan; Sevcenco, Sabina; Csizmarik, Anita; Nyírády, P.; Küronya, Zsófia; Reis, Henning; Maj-Hes, Agnieszka; Shariat, Shahrokh F.; Kramer, Gero; Szarvas, Tibor.

In: Urologia Internationalis, Vol. 101, No. 1, 01.07.2018, p. 65-73.

Research output: Contribution to journalArticle

Darr, C, Krafft, U, Hadaschik, B, Tschirdewahn, S, Sevcenco, S, Csizmarik, A, Nyírády, P, Küronya, Z, Reis, H, Maj-Hes, A, Shariat, SF, Kramer, G & Szarvas, T 2018, 'The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer', Urologia Internationalis, vol. 101, no. 1, pp. 65-73. https://doi.org/10.1159/000489891
Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A et al. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. Urologia Internationalis. 2018 Jul 1;101(1):65-73. https://doi.org/10.1159/000489891
Darr, Christopher ; Krafft, Ulrich ; Hadaschik, Boris ; Tschirdewahn, Stephan ; Sevcenco, Sabina ; Csizmarik, Anita ; Nyírády, P. ; Küronya, Zsófia ; Reis, Henning ; Maj-Hes, Agnieszka ; Shariat, Shahrokh F. ; Kramer, Gero ; Szarvas, Tibor. / The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. In: Urologia Internationalis. 2018 ; Vol. 101, No. 1. pp. 65-73.
@article{8a16bc1541be4dff95ce7efddd21b0a4,
title = "The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer",
abstract = "Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy. Responsive patients were retreated by repeated series of DOC. Results were compared with the clinical parameters as well as overall (OS) and disease-specific survival (DSS). Results: YKL-40 but not PSA serum levels were significantly higher in patients with baseline resistance to DOC (p = 0.035). Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008). High YKL-40 levels were associated with shorter OS (p = 0.037) and DSS (p = 0.017) in patients who received DOC in the first-line setting. In multivariable analysis, ECOG performance status (p = 0.009), presence of any metastases (p = 0.016) and high PSA levels (p = 0.005) remained independent predictors for DSS. Conclusions: YKL-40 may help to identify patients with baseline resistance to DOC and therefore may help to optimize treatment decisions. In accordance, high pre-treatment YKL-40 serum levels were associated with shorter OS and DSS in patients who received DOC as first-line therapy.",
keywords = "Castratation-resistant prostate cancer, Docetaxel, Drug resistance, Prognosis, Prostate cancer, YKL-40",
author = "Christopher Darr and Ulrich Krafft and Boris Hadaschik and Stephan Tschirdewahn and Sabina Sevcenco and Anita Csizmarik and P. Ny{\'i}r{\'a}dy and Zs{\'o}fia K{\"u}ronya and Henning Reis and Agnieszka Maj-Hes and Shariat, {Shahrokh F.} and Gero Kramer and Tibor Szarvas",
year = "2018",
month = "7",
day = "1",
doi = "10.1159/000489891",
language = "English",
volume = "101",
pages = "65--73",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer

AU - Darr, Christopher

AU - Krafft, Ulrich

AU - Hadaschik, Boris

AU - Tschirdewahn, Stephan

AU - Sevcenco, Sabina

AU - Csizmarik, Anita

AU - Nyírády, P.

AU - Küronya, Zsófia

AU - Reis, Henning

AU - Maj-Hes, Agnieszka

AU - Shariat, Shahrokh F.

AU - Kramer, Gero

AU - Szarvas, Tibor

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy. Responsive patients were retreated by repeated series of DOC. Results were compared with the clinical parameters as well as overall (OS) and disease-specific survival (DSS). Results: YKL-40 but not PSA serum levels were significantly higher in patients with baseline resistance to DOC (p = 0.035). Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008). High YKL-40 levels were associated with shorter OS (p = 0.037) and DSS (p = 0.017) in patients who received DOC in the first-line setting. In multivariable analysis, ECOG performance status (p = 0.009), presence of any metastases (p = 0.016) and high PSA levels (p = 0.005) remained independent predictors for DSS. Conclusions: YKL-40 may help to identify patients with baseline resistance to DOC and therefore may help to optimize treatment decisions. In accordance, high pre-treatment YKL-40 serum levels were associated with shorter OS and DSS in patients who received DOC as first-line therapy.

AB - Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy. Responsive patients were retreated by repeated series of DOC. Results were compared with the clinical parameters as well as overall (OS) and disease-specific survival (DSS). Results: YKL-40 but not PSA serum levels were significantly higher in patients with baseline resistance to DOC (p = 0.035). Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008). High YKL-40 levels were associated with shorter OS (p = 0.037) and DSS (p = 0.017) in patients who received DOC in the first-line setting. In multivariable analysis, ECOG performance status (p = 0.009), presence of any metastases (p = 0.016) and high PSA levels (p = 0.005) remained independent predictors for DSS. Conclusions: YKL-40 may help to identify patients with baseline resistance to DOC and therefore may help to optimize treatment decisions. In accordance, high pre-treatment YKL-40 serum levels were associated with shorter OS and DSS in patients who received DOC as first-line therapy.

KW - Castratation-resistant prostate cancer

KW - Docetaxel

KW - Drug resistance

KW - Prognosis

KW - Prostate cancer

KW - YKL-40

UR - http://www.scopus.com/inward/record.url?scp=85049397659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049397659&partnerID=8YFLogxK

U2 - 10.1159/000489891

DO - 10.1159/000489891

M3 - Article

VL - 101

SP - 65

EP - 73

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 1

ER -